Ken Takanashi

We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM™, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM™, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.